Anti-Anxiety Agents

• 

  Subject Areas on Research

  • 3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates. 
  • A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. 
  • A case of infant delirium in the neonatal intensive care unit. 
  • A combined treatment approach to anxiety in the medically ill. 
  • A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. 
  • A prescription for unemployment? Recessions and the demand for mental health drugs. 
  • A probabilistic and individualized approach for predicting treatment gains: an extension and application to anxiety disordered youth. 
  • A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). 
  • Acute tolerance and reversal of the motor control effects of midazolam. 
  • Adinazolam sustained-release treatment of panic disorder: a double-blind study. 
  • Age-related differences in neurosteroid potentiation of muscimol-stimulated 36Cl(-) flux following chronic ethanol treatment. 
  • Alprazolam for endogenous depression. 
  • Alprazolam reduces stress hyperglycemia in ob/ob mice. 
  • An anxiety-like phenotype in mice selectively bred for aggression. 
  • An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. 
  • Anxiety in medically ill older patients: a review and update. 
  • Anxiolytic effects of acute morphine can be modulated by nitric oxide systems. 
  • Anxiolytic effects of nicotine in zebrafish. 
  • Attention bias toward threat in pediatric anxiety disorders. 
  • Benzodiazepine and beta-adrenergic receptor ligands independently stimulate phospholipid methylation. 
  • Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. 
  • Benzodiazepine use and cognitive function among community-dwelling elderly. 
  • Benzodiazepines in the intensive care unit. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. 
  • Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial. 
  • Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. 
  • Contemporary management of comorbid anxiety and depression in geriatric patients. 
  • Defining an appropriate management strategy for social anxiety disorder. 
  • Do benzodiazepines have a role in the prevention or treatment of coronary heart disease and other major medical disorders? 
  • Effect of a single dose of diazepam on balance measures in older people. 
  • Effects of amphetamines and small related molecules on recovery after stroke in animals and man. 
  • Effects of atypical anxiolytic N-phenyl-2-[1-[3-(2-pyridinylethynyl)benzoyl]-4-piperidine]acetamide (JNJ-5234801) on alcohol intake in alcohol-preferring P rats. 
  • Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. 
  • Emergent anxiety after antidepressant initiation: a retrospective cohort study of Veterans Affairs Health System patients with depression. 
  • Endotracheal administration of flumazenil. 
  • Endotracheal flumazenil: a new route of administration for benzodiazepine antagonism. 
  • Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. 
  • Evaluation of temazepam and diphenhydramine as hypnotics in a nursing-home population. 
  • Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. 
  • Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. 
  • Exceptionally high seizure threshold: ECT device limitations. 
  • Explanatory attributions of anxiety and recovery in a study of kava. 
  • Factors associated with antidepressant, anxiolytic, and other psychotropic medication use to treat psychiatric symptoms in the city of São Paulo, Brazil. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. 
  • Generalized anxiety disorder. An important clinical concern. 
  • Generalized anxiety disorder: acute and chronic treatment. 
  • Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. 
  • Impact of hospital type II violent events: use of psychotropic drugs and mental health services. 
  • Impact of symptoms of generalized anxiety disorder on the course of late-life depression. 
  • Inpatient and outpatient patterns of psychotropic drug prescribing by nonpsychiatrist physicians. 
  • Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. 
  • Loop diuretics have anxiolytic effects in rat models of conditioned anxiety. 
  • Management of dyspnea within a rapid learning healthcare model. 
  • Medial septal benzodiazepine receptors modulate hippocampal evoked responses and long-term potentiation. 
  • Midazolam--an anti-emetic? 
  • Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. 
  • Naturalistic follow-up of youths treated for pediatric anxiety disorders. 
  • Neighborhood health center patients who use minor tranquilizers. 
  • Neuropeptides modulate compound postsynaptic potentials in basolateral amygdala. 
  • North Carolina Medicaid recipient management lock-in program: the pharmacist's perspective. 
  • Panic disorder and social phobia: current treatments and new strategies. 
  • Paradoxical reactions in children associated with midazolam use during endoscopy. 
  • Paroxetine in the treatment of generalised anxiety disorder. 
  • Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. 
  • Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. 
  • Pharmacokinetics and clinical effects of sublingual triazolam in pediatric dental patients. 
  • Pharmacotherapy of generalized anxiety disorder. 
  • Physician office visits of adults for anxiety disorders in the United States, 1985-1998. 
  • Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. 
  • Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam. 
  • Psychopharmacologic treatment of children and adolescents with anxiety disorders. 
  • Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. 
  • Psychotropic drugs on general medical and surgical wards of a teaching hospital. 
  • Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. 
  • Reducing long-term diazepam prescribing in office practice. A controlled trial of educational visits. 
  • Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. 
  • Relaxation to assist sleep medication withdrawal. 
  • Role of stress in the etiology and treatment of diabetes mellitus. 
  • SMARTer discontinuation trial designs for developing an adaptive treatment strategy. 
  • Sedation of children for emergency imaging. 
  • Sedative, hypnotic, and antianxiety medication use in an aging cohort over ten years: a racial comparison. 
  • Social anxiety disorder in children and adolescents: epidemiology, diagnosis, and treatment. 
  • Social anxiety disorder under scrutiny. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Suicide risk analysis among patients assigned to psychotropics and placebo. 
  • Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. 
  • The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. 
  • The use of flumazenil in the anxious and benzodiazepine-dependent ECT patient. 
  • Therapist-Reported Features of Exposure Tasks That Predict Differential Treatment Outcomes for Youth With Anxiety. 
  • Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. 
  • Trajectories of change in youth anxiety during cognitive-behavior therapy. 
  • Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications. 
  • Treatment of Anxiety in Patients With Coronary Heart Disease: A Systematic Review. 
  • Treatment of social phobia with gabapentin: a placebo-controlled study. 
  • Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development. 
  • [Benzodiazepines consumption and risk of dependence in institutionalized geriatric patients]. 
  • [Endogenous inhibitors of specific benzodiazepine binding in the cerebral cortex of the bull]. 
  • [Endogenous inhibitors of the specific binding of benzodiazepines in the cerebral cortex]. 
  • [Molecular mechanisms of the pharmacologic action of benzodiazepines]. 
  • κ-Opioid receptors in the central amygdala regulate ethanol actions at presynaptic GABAergic sites.